GBIO
Generation Bio Co.
Biotechnology
Market Cap$36M
5Y Perf.-97.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GBIO vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-69.2%
GBIO vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GBIO | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $36M | $2.57B |
| Revenue (TTM) | $15M | $669M |
| Net Income (TTM) | $-63M | $-609M |
| Gross Margin | 90.8% | 83.6% |
| Operating Margin | -5.5% | -83.9% |
| Total Debt | $94M | $1.28B |
| Cash & Equiv. | $76M | $434M |
GBIO vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GBIO
RARE
| Stock | Jun 20 | Feb 26 | Return |
|---|---|---|---|
| Generation Bio Co. (GBIO) | 100 | 2.5 | -97.5% |
| Ultragenyx Pharmace… (RARE) | 100 | 30.8 | -69.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GBIO vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GBIO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
GBIO
Generation Bio Co.
The Growth Play
GBIO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 236.9%, EPS growth -0.7%
- 236.9% revenue growth vs RARE's 20.1%
- +36.9% vs RARE's -21.8%
Best for: growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Income Pick
RARE is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.42
- -59.4% 10Y total return vs GBIO's -97.8%
- Lower volatility, beta 1.42, current ratio 2.48x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GBIO | 236.9% revenue growth vs RARE's 20.1% |
| Quality / Margins | RARE | -91.0% margin vs GBIO's -410.1% |
| Stability / Safety | RARE | Beta 1.42 vs GBIO's 1.68 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | GBIO | +36.9% vs RARE's -21.8% |
| Efficiency (ROA) | GBIO | -34.1% ROA vs RARE's -45.8%, ROIC -63.2% vs -89.4% |
GBIO vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
GBIO vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRARELAGGINGGBIO
GBIOGeneration Bio Co.
1leads
RAREUltragenyx Pharmaceut…
2leads
6 Total Categories
CATEGORYLEADERvs GBIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RARE4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GBIO5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RARE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RARE leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 43.8x GBIO's $15M. Profitability is closely matched — net margins range from -91.0% (RARE) to -4.1% (GBIO). On growth, RARE holds the edge at -2.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $15M | $669M |
| EBITDAEarnings before interest/tax | -$80M | -$536M |
| Net IncomeAfter-tax profit | -$63M | -$609M |
| Free Cash FlowCash after capex | -$115M | -$487M |
| Gross MarginGross profit ÷ Revenue | +90.8% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -5.5% | -83.9% |
| Net MarginNet income ÷ Revenue | -4.1% | -91.0% |
| FCF MarginFCF ÷ Revenue | -7.5% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -78.9% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +64.2% | -17.2% |
RARE leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — GBIO and RARE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $36M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $53M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.27x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.81x | 3.82x |
| Price / BookPrice ÷ Book value/share | 0.41x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — GBIO and RARE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
GBIO leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
GBIO delivers a -94.8% return on equity — every $100 of shareholder capital generates $-95 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), RARE scores 4/9 vs GBIO's 2/9, reflecting mixed financial health.
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -94.8% | -6.1% |
| ROA (TTM)Return on assets | -34.1% | -45.8% |
| ROICReturn on invested capital | -63.2% | -89.4% |
| ROCEReturn on capital employed | -53.6% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 4 |
| Debt / EquityFinancial leverage | 1.09x | — |
| Net DebtTotal debt minus cash | $17M | $842M |
| Cash & Equiv.Liquid assets | $76M | $434M |
| Total DebtShort + long-term debt | $94M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
GBIO leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RARE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RARE five years ago would be worth $2,281 today (with dividends reinvested), compared to $165 for GBIO. Over the past 12 months, GBIO leads with a +36.9% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors RARE at -17.8% vs GBIO's -51.5% — a key indicator of consistent wealth creation.
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -1.9% | +10.7% |
| 1-Year ReturnPast 12 months | +36.9% | -21.8% |
| 3-Year ReturnCumulative with dividends | -88.6% | -44.5% |
| 5-Year ReturnCumulative with dividends | -98.3% | -77.2% |
| 10-Year ReturnCumulative with dividends | -97.8% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -51.5% | -17.8% |
RARE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GBIO and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
RARE is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than GBIO's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GBIO currently trades 76.8% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.42x |
| 52-Week HighHighest price in past year | $6.95 | $42.37 |
| 52-Week LowLowest price in past year | $3.00 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +76.8% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 39.2 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 0 | 1.8M |
Evenly matched — GBIO and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | GBIOGeneration Bio Co. | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $51.50 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RARE leads in 2 of 6 categories (Income & Cash Flow, Total Returns). GBIO leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallUltragenyx Pharmaceutical I… (RARE)Leads 2 of 6 categories
Loading custom metrics...
GBIO vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GBIO or RARE a better buy right now?
For growth investors, Generation Bio Co.
(GBIO) is the stronger pick with 236. 9% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GBIO or RARE?
Over the past 5 years, Ultragenyx Pharmaceutical Inc.
(RARE) delivered a total return of -77. 2%, compared to -98. 3% for Generation Bio Co. (GBIO). Over 10 years, the gap is even starker: RARE returned -59. 4% versus GBIO's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GBIO or RARE?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.
(RARE) is the lower-risk stock at 1. 42β versus Generation Bio Co. 's 1. 68β — meaning GBIO is approximately 18% more volatile than RARE relative to the S&P 500.
04Which is growing faster — GBIO or RARE?
By revenue growth (latest reported year), Generation Bio Co.
(GBIO) is pulling ahead at 236. 9% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -0. 7% for Generation Bio Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GBIO or RARE?
Ultragenyx Pharmaceutical Inc.
(RARE) is the more profitable company, earning -85. 4% net margin versus -661. 9% for Generation Bio Co. — meaning it keeps -85. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -715. 8% for GBIO. At the gross margin level — before operating expenses — GBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GBIO or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GBIO or RARE better for a retirement portfolio?
For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Generation Bio Co. (GBIO) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, GBIO: -97. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GBIO and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(GBIO: -78.9% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.